CG Oncology (NASDAQ:CGON) Earns Buy Rating from HC Wainwright

CG Oncology (NASDAQ:CGON - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They currently have a $75.00 price target on the stock. HC Wainwright's price target would suggest a potential upside of 113.68% from the company's previous close.

Other equities analysts have also issued reports about the company. Cantor Fitzgerald restated an "overweight" rating and set a $75.00 target price on shares of CG Oncology in a research report on Thursday. Morgan Stanley began coverage on shares of CG Oncology in a report on Tuesday, February 20th. They set an "overweight" rating and a $55.00 price objective for the company. Finally, The Goldman Sachs Group began coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They set a "neutral" rating and a $42.00 price target on the stock.

CG Oncology Stock Down 3.2 %

Shares of NASDAQ:CGON traded down $1.17 during midday trading on Monday, hitting $35.10. The company had a trading volume of 1,455,301 shares, compared to its average volume of 653,807. CG Oncology has a 12 month low of $28.55 and a 12 month high of $50.23. The business has a fifty day moving average of $39.63.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CG Oncology stock. BNP Paribas Financial Markets acquired a new stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 11,198 shares of the company's stock, valued at approximately $492,000. 26.56% of the stock is owned by institutional investors.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.